Session » Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster I

Date: Monday, November 6, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1669

Anti-Mitochondria DNA Antibody As an Improved Biomarker for Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1666

Anti-Mitochondrial Autoantibodies in Systemic Lupus Erythematosus and Their Association with Disease Manifestations

9:00AM-11:00AM: Abstract Number: 1674

Combining Medications That Lower Systemic Oxidative Stress Is Associated with Less Atherosclerosis in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1671

Complement C4 Gene Copy Number Variations Bestow Large Ranges of Serum C4 Protein Levels in Chinese Patients with Systemic Lupus Erythematosus (SLE) and Contribute to Organ and Cardiovascular Damages over Time

9:00AM-11:00AM: Abstract Number: 1672

Cytokines and Autoantibody Cluster-Interaction in Systemic Lupus Erythematosus. a Systems Medicine Approach

9:00AM-11:00AM: Abstract Number: 1663

De Novo Mutation in ΑCΑCΒ in Childhood Onset SLE Highlights a Novel Role As Modulator of Nucleic Acid Sensor-Driven Type I Interferon Responses

9:00AM-11:00AM: Abstract Number: 1662

High Type I Interferon Activity Is Associated with Active Class Ⅲ/Ⅳ Lupus Nephritis in European-American Lupus Patients Independent of dsDNA Antibodies

9:00AM-11:00AM: Abstract Number: 1670

HMGB1-TLR4 Axis in Patients with Neuropsychiatric Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1673

Human C4 Gene Copy Number Influences Cell-Bound Complement Activation Product (CB-CAP) C4d in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1668

Identification of a Serum Measure of Lupus Nephritis Activity That Detects Molecular Pathways and Mechanisms Implicated in Renal Damage

9:00AM-11:00AM: Abstract Number: 1659

Identification of Long Noncoding RNA RP11-2B6.2 As a Positive Regulator through Type I Interferon Pathway in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1667

Increased Levels of BAFF in SLE Patients Correlates with Neutrophil Activation and Autoantibody Production

9:00AM-11:00AM: Abstract Number: 1655

Interferon b Blockade Rescues Human BM-MSC Osteoblastogenesis Defects in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1658

Interferon Related Soluble Mediator Concentrations Significantly Correlate with Disease Activity in SLE Patients with Active Interferon Pathways

9:00AM-11:00AM: Abstract Number: 1660

Prolactin Induces an Interferon Signature in Monocytes and Drives IRF1-HAT Interactions

9:00AM-11:00AM: Abstract Number: 1664

Serum FAS, Ferritin, Igfbp2, sTNFR2 As Markers for Tracking Mucocutaneous and Musculoskeletal Flares in SLE Patients

9:00AM-11:00AM: Abstract Number: 1675

SLE Comprises Four Immune-Phenotypes, Which Differ Regarding HLA-DRB1 and Clinical Associations

9:00AM-11:00AM: Abstract Number: 1657

SLE Patients with Active Interferon Pathways Showed More Systemic Disease Involvement Than Patients with Inactive Interferon Pathways

9:00AM-11:00AM: Abstract Number: 1665

Soluble Programmed Cell Death Protein 1 As a Biomarker for Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1661

STAT4 Regulates Pathogenic IL-21 and IFN-γ in Tfh Cells in Murine and Human Lupus

9:00AM-11:00AM: Abstract Number: 1656

Type I Interferon Drives the Dysregulation of Plasmacytoid and Myeloid Dendritic Cells in Systemic Lupus Erythematosus and Antiphospholipid Syndrome

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].